| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2146/AJHP090285 |
| P698 | PubMed publication ID | 20516468 |
| P2093 | author name string | Daniel G Dauner | |
| Robert E Nelson | |||
| Donna C Taketa | |||
| P2860 | cites work | In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci | Q24550612 |
| Tigecycline: a new glycylcycline antimicrobial agent | Q28247555 | ||
| Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 | ||
| In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci | Q34162130 | ||
| Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae | Q34624359 | ||
| PBP 2a mutations producing very-high-level resistance to beta-lactams | Q35547377 | ||
| Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects | Q35879080 | ||
| Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. | Q36422630 | ||
| Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. | Q36735202 | ||
| Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy | Q36763997 | ||
| In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus | Q36815290 | ||
| Clinical profile of ceftobiprole, a novel beta-lactam antibiotic | Q36815295 | ||
| Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections | Q36916071 | ||
| In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models | Q36932924 | ||
| Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity | Q37030780 | ||
| Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia | Q37119259 | ||
| Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. | Q37733667 | ||
| In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections | Q39077347 | ||
| Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms | Q39077719 | ||
| BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | Q39650937 | ||
| Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers | Q40967997 | ||
| Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers | Q40968003 | ||
| Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus | Q41092910 | ||
| Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus | Q41336401 | ||
| Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. | Q41473443 | ||
| Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin | Q41847350 | ||
| Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin | Q42112713 | ||
| Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. | Q42584480 | ||
| Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates | Q42747697 | ||
| Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). | Q46667419 | ||
| A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections | Q46787486 | ||
| In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin | Q46792584 | ||
| Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department | Q55897489 | ||
| Linezolid: an oxazolidinone antimicrobial agent | Q78721705 | ||
| In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection | Q80193908 | ||
| Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model | Q80557153 | ||
| P433 | issue | 12 | |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| P304 | page(s) | 983-993 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | American Journal of Health-System Pharmacy | Q15754037 |
| P1476 | title | Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus | |
| P478 | volume | 67 |
| Q37916805 | Advances in antibacterial therapy |
| Q35117981 | Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) |
| Q26796463 | Ceftobiprole for the treatment of pneumonia: a European perspective |
| Q43048139 | Ceftobiprole: Farewell or just a delay? |
| Q38242081 | Current and emerging drugs for acute bacterial skin and skin structure infections: an update |
| Q55443184 | In silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens. |
| Q38035171 | Inhibitors targeting on cell wall biosynthesis pathway of MRSA. |
| Q92304798 | Mechanisms of action and antimicrobial activity of ceftobiprole |
| Q38099393 | Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia. |
| Q28066877 | Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations |
| Q40049973 | Treatment of Staphylococcus aureus Infections |
| Q38462842 | Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice |
Search more.